Skip to main content
. 2024 Jun 25;42(9):955–1002. doi: 10.1007/s40273-024-01399-3
This review examined how existing health economic models (i.e., tools to demonstrate the monetary value of a new treatment and its impact on a healthcare system) are used to evaluate drugs for relapsed/refractory multiple myeloma; in particular, it evaluated challenges associated with key methodological concepts, including conceptualization, model structure, uncertainty analyses, model validation, and transparency; and how health economic models addressed differences in the line of therapy and exposure to prior treatment.
Published economic models in relapsed/refractory multiple myeloma mostly adhere to conventional methodology, such as cohort partitioned survival or Markov models, as opposed to more complex, individual patient model types due to the higher data requirements associated with the latter. Less than half of the models included a step to verify the results, potentially reflecting the variance in validation reporting between health technology assessment submissions and journal articles, where journals typically offered a more comprehensive coverage.